Академический Документы
Профессиональный Документы
Культура Документы
BMS PV Integration
Document Status /
Version:
DP1 0.1
Project Reference
Code:
XXX
Customer Business
Area:
Patient Safety
Project Phase:
Primary Project
Manager:
Delivery Organisation
Project Manager:
Karthick Sukumaran
Project Sponsor:
Prepared by:
Robert Sanchez
Date Raised:
Expiry Date:
14- Apr-2014
Target Completion
Date (this phase):
30-May-2014
Document Pre-Approval
Area
Approval
Financial
Yes
Commercial
Yes
Resources
Yes
Project Methodology
Yes
Integrated Assurance
Yes
Architecture
Yes
Run
Yes
Date
Disclaimer
If you are reading a copy of this document (i.e. print out of controlled electronic document or an
electronic copy of a wet ink signed paper document) you may be reading an uncontrolled version.
Before making updates, please ensure that you are using the latest version.
07/08/09
Page 1 of 12
Version Control
Version
Date
Description of Changes
Author
1.0
22-May-2014
Initial version
Gopi Govindarajan
1.1
28-May-2014
Ritika Jain
Referenced Documents
Name
Version
Location
1.0
LDMS_XXX_XXXXXX
07/08/09
Page 2 of 12
1. Summary
1.1
1.1.1 Summary
AstraZenecas acquisition of the BMS Diabetes Portfolio has resulted in the need for
incorporating BMS Patient safety, AE data and Source documentation for the drugs under
consideration into its existing Adverse Event Reporting System (Sapphire).
AstraZeneca uses Sapphire as an Adverse Event Reporting System (AERS) which captures
clinical and post marketing adverse events. BMS will be using ARGUS as their Adverse Event
Reporting System (AERS) system. Currently BMS is in the process of migrating from their
existing AERS system CARES into ARGUS.
ARGUS V 7.0.3.1 will be used as the BMS Global Drug Safety System for processing
worldwide adverse event case reports for drugs.
1.1.2 Business Requirements
The Business & User Requirements Specification have been captured in the following key
document:
1. BMS Data Migration Questionnaire Developed by Cognizant with details on the
agreed scope for the project in discussion with AZ and BMS Stakeholders
This document forms the baseline scope for the project going forward.
Note: Any further changes required will need to be handled by the formal change control
process to assess impact on time, cost and quality.
1.1.3 Performance to Date
We are satisfied that the project has completed the necessary deliverables to
the level of detail that can support this project moving forward.
All risks are up to date and there are no known major issues at this time.
Although the scope of the functionality has increased, this is not significant
and is within acceptable parameters.
1.2
07/08/09
Page 3 of 12
GREE
N
From DP3 the overall funding required for the project over a 35 weeks period (Jun 2014 - Jan
2014) is $XXX USD, which includes a 15% contingency. Note: This includes both project and
some of the business process outsourcing costs.
Agreed budget from DP1 is still valid and the project will deliver within the budget agreed in
DP1. This is based on the actuals to date and revised estimates from Cognizant (increase of
$XXXX USD).
ACTIVITY BY GDD IS
Line item
Previous
Work
Package(s)
Justify
Initiate & Plan
Analyse & Design
Build to Close
Total
Contingency
Total Including
Contingency
This Work
Package
Estimate of
remaining
work beyond
this work
package
Actuals to
date
Totals
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Scope
2.1.1 In Scope:
Drug Types :
o Clinical/Investigational
o Marketed
Cases Type:
o Transactional case data (current case version) : Open & cases still being followedup
o Historical case data versions/ audit trail not in scope.
o Only Closed Cases are in scope for this project
Data Migration
o Case Data Migration:
AWARE Safety Data and Adverse Events (for the drugs in scope) into
Sapphire
07/08/09
Page 4 of 12
o
o
Periodic reports
Updates to business and reporting rules in Sapphire
Data migration from AWARE to Jasper is considered out of scope for this project
Data migration from Empirica to AZ SMS is considered out of scope for this project
Data migration from Aris J to ClinicalWorks is considered out of scope for this project
Data migration from AWARE to PSI/SSI is considered out of scope for this project
No audit data will be migrated from AWARE to SAPPHIRE
Migration of paper based source documents is not in scope
Archival of BMS data and documents is not in scope of this project
No change will be done in RAVE and IMPACT interfaces
Any upgrade of existing systems is considered out of scope
AZDD upgrade is considered out of scope.
No additional data will be transferred from Sapphire to ClinicalWorks as a result of the
transfer from AWARE.
07/08/09
Page 5 of 12
12. Data transformations from BMS to sapphire are considered to be minimal and any
changes this would need to be reviewed again after the analysis of production ARGUS
data.
Should these assumptions prove incorrect the work may be delayed and/or costs may increase.
Risk Description
Owner
Kamlesh Shah
AstraZeneca
Cognizant
Cognizant
AstraZeneca / Cognizant
Cognizant / AstraZeneca
AstraZeneca
2.3
Dependencies
The project is dependent on the successful delivery of AWARE Migration by Sep 2014 as the
project can have the extract from production only after that.
The project is dependent on the successful completion of the Patient Safety Consolidation
project for the document migration approach.
The project is dependent upon service maintenance window being agreed that adheres to the
project schedule to avoid unnecessary delays.
The project is dependent upon the Maintenance projects required for the current system being
managed independently.
07/08/09
Page 6 of 12
2.4
Approach
As the user base is relatively small the project will go live to all users at the same time.
Data Migration
The approach has been documented in the DP512 Data Migration approach document, see
high level summary below:
Case Data to Sapphire
Establish data transfer between BMS and AZ
Copy BMS data in AZ network for migration
Upload BMS database dump into temporary schema
Extract, transform and load case data from temporary
schema to Sapphire transaction DB via ETL as per defined mapping rules
Validate and test data
Push data from transactional to Reporting data mart using existing ETL job
Push data to SMS
Archive data to Gold repository
Source Documents to Sapphire
Establish data transfer between BMS and AZ
Copy BMS data in AZ network for migration
Extract and load BMS source documents to Sapphire file system
Validate and test
Archive to Gold repository
2.5
Business Case
The short business case has been created and supplied by XXX for XXXXX and approved by
PES on dd Month YYYY.
The full business case is now ready and has been approved by PES and PIB.
07/08/09
Page 7 of 12
3.2
MILESTONE
TARGET
DATE
30-May-2014
MILESTONE
DESCRIPTION
MILESTONE
TARGET
DATE
25-Jul-2014
MILESTONE
DESCRIPTION
Analysis
MILESTONE
TARGET
DATE
15-Aug-2014
MILESTONE
DESCRIPTION
Design
07/08/09
Page 8 of 12
MILESTONE
TARGET
DATE
17-Oct-2014
MILESTONE
DESCRIPTION
Build
MILESTONE
TARGET
DATE
05-Dec-2014 Test
MILESTONE
DESCRIPTION
MILESTONE
MILESTONE
TARGET
DESCRIPTION
DATE
05-Feb-2015 Deployment
4. Additional Responsibilities
Cognizant will be responsible for the delivery of the solution from the analysis to the
end of System Test.
Cognizant will be responsible for the data migration of diabetes cases and Source
documents with support from AWARE(ARGUS).
Cognizant will be responsible for copying the source data in programme level
repository and AZ will be responsible for archiving it
IBM will be responsible for providing the Infrastructure required meeting the
requirements.
AZ will take over all case handling activities related to the diabetes products at the end
of migration
AZ will be responsible for facilitating communications with BMS, SMS and any other
vendor/team
07/08/09
Page 9 of 12
Forecast cost
2014
Forecast cost
Total
$
$0
$
$0
5.2
Cost Contingency
We have been advised that the service introduction costs could increase as the new
guidance states that they should be approximately 3% of development costs for
applications that will be developed and managed by Cognizant.
Travel costs were not included as part of the approved business case as we did not
have this guidance available then so we will need to use a proportion of the overall
contingency to fund this.
Estimated Costs
2014
2015
Total
Hardware
Internal resource GDD IS
Internal resource EPD
Internal resource Global Patient Safety
Internal resource BMS Business
Internal resource BMS It
External resource Cognizant
Third Party Oracle
Third Party Informatica
Third Party IBM
Service Ongoing
Total
Cost Contingency
Total: This Delivery Organisation
07/08/09
$0
$0
$0
$0
$0
$0
$0
$0
$0
Page 10 of 12
$0
$0
2010
Service Ongoing
(3,000 per month *12)
Total
$0
$0
2011
$0
$0
Total
$0
$0
$0
$0
$0
$0
$0
$0
$0
07/08/09
Description
Page 11 of 12
Instructions appendix:
Document pre-approval relates to the contents of this document being approved prior to
presentation at a relevant Governance Board. Details of what is being approved by area are
given below:
Area
Will the appropriate funding will be in the right place, at the right
time and in the right currency to pay for the remaining phases of
the project?
Are the third party costs within the business case based on
appropriate commercial arrangements?
Will the right SET resources be available at the right time to deliver
the next phase of the project?
Project
Methodology
Integrated
Assurance
Architecture
Financial
Commercial
Resources
Run
07/08/09
Page 12 of 12